Pfizer Uses Lipid Nanoparticles for mRNA Delivery

Pfizer Inc. is detailing the critical role of lipid nanoparticles (LNPs) in the delivery of messenger RNA (mRNA) technology. These small fat bubbles act as delivery vehicles, encapsulating fragile mRNA molecules, protecting them from degradation within the body, and facilitating their entry into target cells.

mRNA technology leverages the body's natural protein-making capabilities. When mRNA carries instructions to produce a specific protein, such as the spike protein of the SARS-CoV-2 virus, it can temporarily transform cells into protein factories. This process induces an immune response, as seen with mRNA COVID-19 vaccines.

According to Pfizer, LNP technology was crucial to the success of the mRNA COVID-19 vaccines. The company is now expanding its mRNA programs to develop new vaccines and therapies, with LNPs remaining central to these advancements.

The development and manufacturing of LNP technology reside within Pfizer's Pharmaceutical Sciences Group. Researchers, including Vice President Nicholas Warne, work to optimize LNP formulation and production processes under rigorous quality and safety standards. Pfizer highlights the advantages of an integrated approach, where formulation and manufacturing experts collaborate to ensure a smooth transition from research to large-scale production.

Pfizer is continuously advancing LNP technology to target new cell types and carry different payloads. For instance, LNPs designed to treat rare genetic diseases must be engineered to reach specific organs or tissues. The company's extensive experience in vaccine and drug manufacturing supports the ongoing development of this innovative delivery system.